Download Citation
Article Source:
Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis
Mori A,
Saito T,
Takahashi M,
Shibata M,
Tsuji G,
et al.
(2020)
Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
PLOS ONE 15(12): e0243729.
https://doi.org/10.1371/journal.pone.0243729